Ashkenazi has been key to managing the windfall in revenue and wave of investor optimism from Eli Lilly's diabetes injection Mounjaro and obesity drug Zepbound.https://www.cnbc.com/2024/06/17/eli-lilly-cfo-anat-ashkenazi-on-managing-soaring-demand-for-glp-1s.html[Collection]